Krystal Biotech, Inc. (KRYS) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

a rare genetic disease of the skin that is a strong fit with our HSV-1 gene delivery platform and our commercial footprint. Simmo will share more about this program later on the call. Financially, we're strong and well-positioned to execute on our strategic growth plans and deliver value to shareholders. Moving now to our 3Q results, we are pleased to report another quarter of revenue growth with net Vycevic revenue coming in at $97.8 million. The patient pausing impacts due to summer holidays that we observed earlier last quarter were mitigated by patient ads and early traction in Europe. Net Weisjeweck revenues reported here does include a contribution from Europe following our launch in Germany in late August. This brings total net Weisjeweck revenues since launch to over $623 million. Gross margins were 96% for the quarter. Gross-to-net dynamics were stable as with prior quarters. I'm happy to report continued acceleration in new reimbursement approvals in the US. Our team added over 40 new approvals since our last earnings call update, bringing the total number of reimbursement approvals in the US to over 615. This is now our second sequential quarter of reimbursement approval acceleration and a reflection of our field team's efforts, as well as the ongoing sales force expansion. Our expanded field force is now fully hired and being deployed as training is completed. Full impact is expected in early 2026. We're also happy to report continued expansion of our prescriber work, reflecting increased penetration into the community setting, with the total number of prescribers in the U.S. now exceeding 450. I would like to highlight a recent milestone achieved in the U.S., which was the FDA approval of our updated Vizuvac label. This label update expanded the Vizuvac-...